A clinical study to evaluate the efficacy of lakshadi guggulu and Haridra (lakadong turmeric) in improving Vitamin D deficiency in asthikshaya condition of NE region - NA

开始日期2025-03-03

申办/合作机构-

NCT06757244

/ Not yet recruiting临床2期IIT

DOVIPA, a Phase II Study Evaluating Efficacy and Safety of DOstarlimab and Oral VItamin D3 with Folinic Acid, 5FU, Irinotecan Plus Oxalipaltin (mFOLFIRINOX) in Non Pretreated Metastatic PAncreatic Cancer

The goal of this clinical trial is to estimate the antitumor response of mFOLFIRINOX + Dostarlimab + oral HD vitamin D3 in patients with non-pretreated histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas. The patients must have an Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) 0 or 1 and adequate organ functions.
The main objective of the study will be assessed by estimating Objective response rate (ORR) according to Response Evaluation Criteria version 1.1 (RECIST 1.1) in patients with pancreatic adenocarcinoma and measurable disease.
The Secondary objectives are :
* To assess the safety and tolerability of mFOLFIRINOX + Dostarlimab + HD Vitamin D according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 by evaluating the Median Progression Free Survival (mPFS) in months, the Median Overall Survival (mOS) in months, the Median Duration of Response (mDOR) in months and Clinical benefit rate according to RECIST 1.1 (CBR)
* To further evaluate the antitumor efficacy of mFOLFIRINOX + Dostarlimab + oral HD Vitamin D by evaluating the type, frequency, and severity of treatment-emergent adverse events (TEAEs); adverse events of special interest (AESIs); safety laboratory findings There are also exploratory objectives to better understand the pancreatic adenocarcinoma.
Participants will be cared for in the digestive oncology department. A selection review will be carried out to check compliance with the study eligibility criteria. Patients included in the study will be treated with 4 cycles of induction therapy. Each cycle lasts 6weeks and includes chemotherapy such as mFolfirinox D1,D15 and D29, combined with dostarlimab 500 mg every 3 weeks and daily oral vitamin D3.
At the end of the induction treatment period, maintenance treatment will be instituted with LV5FU chemotherapy combined with dostarlimab 1000 mg every 6 weeks and daily oral vitamine D3. Treatment will be maintained until progression or unacceptable toxicity.
Throughout this period, patients will be monitored for their safety. Imaging examinations will also be carried out to monitor the progression of tumour disease.

开始日期2025-01-15

申办/合作机构

Hopital Foch

[+1]

NCT06736002

/ Not yet recruitingN/AIIT

Effects of Mega-dose Vitamin D Pulse and Maintenance Therapy on Seizure Frequency, Fatigue, and Quality of Life: a Prospective Study

We inform consent overall process of this trial study through face-to-face use of the IRB, clarify patient questions, and allow subjects to fully understand the trial study.

开始日期2025-01-01

申办/合作机构

国立成功大学医学院附属医院

100 项与维生素D3 相关的临床结果

登录后查看更多信息

100 项与维生素D3 相关的转化医学

登录后查看更多信息

100 项与维生素D3 相关的专利（医药）

登录后查看更多信息

19,012

项与维生素D3 相关的文献（医药）

2025-12-01·IMMUNOLOGIC RESEARCH

Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells

Article

作者: Naseri, Bahar ; Baradaran, Behzad ; Ghahramanipour, Zahra ; Sohrabi, Sepideh ; Karimzadeh, Hadi ; Mardi, Amirhossein ; Baghbani, Elham ; Masoumi, Javad

Arginine vasopressin (AVP) has disparate impacts on immune responses by divergent receptors on cells including DCs. This study was conducted with the aim of investigating the impact of AVP on the maturation and expression of the inhibitory immune checkpoint molecules in tolerogenic monocyte-derived DCs. CD14 marker was used to separate monocytes from peripheral blood mononuclear cells (PBMCs) by MACS method. To differentiate monocytes from DCs, we utilized GM-CSF and IL-4 cytokines. Tolerogenic DCs were generated using vitamin D3 and dexamethasone. We added LPS and AVP to the culture medium on day 6 after incubation of DCs at 37 °C. Finally, we assessed the surface molecules by flow cytometry and used real-time PCR to evaluate the expression of genes related to the inhibitory immune checkpoints. Based on the obtained data, AVP increased the expression of CD11c (P ≤ 0.0001), HLA-DR (P ≤ 0.01), and CD86 (P ≤ 0.01) in AVP-mDCs. Also, the expression of all the immune checkpoint genes including CTLA-4 (P ≤ 0.001), BTLA (P ≤ 0.001), PDL-1 (P ≤ 0.05), B7H7 (P ≤ 0.001), LAG3 (P ≤ 0.01), and VISTA (P ≤ 0.001) in AVP-mDCs was increased in comparison to the control group. Vasopressin caused the generation of mature and tolerogenic DCs. Our data may help to consider AVP-mDCs to take part in autoimmune disease therapy, transplanted tissue rejection impedance, and allergies.

2025-03-01·Infectious disorders drug targets

Breakthrough Opportunities of Nanotheranostics in Psoriasis: From Pathogenesis to Management Strategy

Article

作者: Sharma, Himanshu ; Singh, Abhishek ; Kumar, Prashant

Background::

In this paper, we have discussed recent advances in our understanding of the aetiology of psoriasis, particularly as they relate to aryl hydrocarbon receptors in DCs, Langerhans cells, macrophages, signal transducer and activator of transcription 3 pathways, and dermal vascular endothelial cells. Here, we have shown that the ability to target specific cellular and molecular components of psoriasis pathogenesis with nanoscale precision using phos-phodiesterase 4 inhibitors represents a transformative opportunity to address the complex nature of this dermatological condition.

Objective::

In this review, we have examined the molecular mechanisms behind the pathogenic features of psoriasis and new treatments being tested in clinical settings. There is research being done on new treatments created in the last ten years. This field highlights the advantages of nan-otechnological technologies as cutting-edge candidates for drug delivery systems in psoriasis and other inflammatory chronic skin disorders.

Future Developments::

Nanotechnology-based treatments currently under study show good effi-cacy and low side effect profiles. However, long-term prospective trials are required to demon-strate long-term safety and effectiveness. Phosphodiesterase inhibitors, Janus kinase inhibitors, nonsteroidal anti-inflammatory drugs, combinations of vitamin D3 derivatives and corticoster-oids, and coal tar formulations are some of the newer topical treatments for psoriasis.

Conclusion::

The psoriasis treatment continues to involve conventional medications (i.e., medi-cines that are generally acknowledged as either normal therapy or outdated remedies), whether used topically or orally. Nonetheless, we are starting to see initiatives to create pharmaceuticals and biosimilars with better therapeutic results, fewer side effects, and greater efficacy

2025-03-01·ENZYME AND MICROBIAL TECHNOLOGY

Identification of a bacteria P450 enzyme from B. megaterium H-1 with vitamin D3 C-25 hydroxylation capabilities

Article

作者: Zhang, Xiaomei ; He, Fan ; Zhou, Jingyi ; Xu, Zhenghong ; He, Yulin ; Li, Hui ; Shi, Jingsong ; Hou, Yina

Calcidiol (25(OH)VD₃) and calcitriol (1α,25(OH)₂VD₃) are active vitamin D₃ with high medicinal value, which can maintain calcium and phosphorus balance and treat vitamin D deficiency. Microbial synthesis is an important method to produce high-value-added compounds. It can produce active vitamin D₃ through the hydroxylation reaction of P450, which can reduce the traditional chemical synthesis steps, and greatly improve the production efficiency and economic benefits. In this work, Bacillus megaterium H-1 was screened for its ability to produce 25(OH)VD₃ and 1α,25(OH)₂VD₃ from vitamin D₃. A new highly inducible vitamin D₃ hydroxylase CYP109E1-H was identified from B. megaterium H-1 through searching for transcripts with cytochrome P450 structural domains, combining the transcriptome sequencing with functional expression in Bacillus subtilis WB600. Biotransformation in recombinant B. subtilis confirmed that CYP109E1-H has C-25 hydroxylase activity towards vitamin D₃. CYP109E1-H is a natural mutant of CYP109E1 with greater stereoselectivity and it is a new vitamin D₃ mono-hydroxylase. The cloning and characterization of the CYP109E1-H gene provide useful information on the structural basis for improving the regional and stereoselectivity of the CYP109E gene.

290

项与维生素D3 相关的新闻（医药）

2025-01-13

·日健中外制药

“艾”骨说 | 一“钙”而论？预防骨质疏松可不简单！

随着我国人口老龄化的加剧，骨质疏松症患病率快速攀升，已成为我国重要的公共健康问题1，但部分人群认知仍停留在“单纯补钙即可预防骨质疏松”的观念上。补钙的确是预防骨质疏松的一项重要措施，但同时也需要其他手段协助，且不合理的补钙可能引起严重后果2。今天，让我们一起走进骨质疏松的世界，了解防治骨质疏松的“不简单”之处！点击查看视频骨质疏松并非老年人专属！骨质疏松症是一种与增龄相关的骨骼疾病3，的确好发于老年人群，但近些年，由于年轻人存在一些不良的生活习惯，包括体力活动少、吸烟、过量饮酒、日照减少、营养不良等，都导致了骨质疏松症的加速出现3,4。此外，遗传因素也会影响骨质疏松的发生，部分基因的突变削弱了骨骼的正常发育，导致骨骼矿物资密度降低，甚至在青少年时期便出现这种特发性骨质疏松5。因此，骨质疏松并非老年人专属，年轻人也需注意！防治骨质疏松，补钙大有学问！骨质疏松大多都是缺钙引起的，但即使部分人可能并不缺钙，同样可能患有骨质疏松，比如药源性骨质疏松，便是由于部分药物（如糖皮质激素、质子泵抑制剂、抗凝剂等）的应用，影响了钙的吸收和代谢，进而导致了骨质疏松1,6，因此，在补钙的基础上，还需要补充维生素D来促进钙的吸收，促进钙在骨骼中的沉积并使骨骼矿化1。此外，不合理的补钙不但可能没有防治效果，甚至可能带来一些严重后果，比如吃了很多钙片，既没有吸收，又没有排出体外，那么可能会引起高钙血症的，引起尿路结石、胆结石或者前列腺结石，严重者会有生命危险2，因此钙要补，但需要一个规范的剂量，目前指南建议成人每日元素钙的摄入量为800mg，50岁及以上人群每日元素钙的摄入量为1000~1200 mg，而我国居民每日膳食约摄入元素钙400mg，因此通过其他钙剂补充500~600mg即可1。除了补钙，我们还要做到这些！生活方式管理是防治骨质疏松的基础，健康的生活方式包括戒烟，限酒，避免过量饮用咖啡及碳酸饮料；加强营养，均衡膳食；保证充足的日照；规律运动；尽量避免或少用可能引起骨质疏松的药物；避免跌倒1。在骨健康基本补充剂方面，除了钙的补充，维生素D也必不可少，首先建议接受充足的阳光照射，对于维生素D 缺乏或不足者，可尝试每日口服维生素D3 1000～2000IU1。药物也是骨质疏松防治必不可少的一环，目前拥有了多种抗骨质疏松药物1，如骨吸收抑制剂、骨形成促进剂、双重作用药物、活性维生素D及其类似物等其他机制类药物、以及中成药均是治疗骨质疏松的有效手段。其中艾地骨化醇作为新一代的活性维生素D衍生物，相较阿法骨化醇，可显著增加患者骨密度、降低患者骨折风险，是改善骨质疏松的优选治疗方案7。参考文献（向上滑动阅览） 1. 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022). 中华内分泌代谢杂志，2023，39(05):377-406. 2. 喻恒锋.浅谈骨质疏松症(科普).第十四届国际骨质疏松研讨会暨第十二届国际骨矿研究学术会议论文集.Ed.江西省人民医院骨质疏松门诊;,2014,115-117. 3. 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 原发性骨质疏松症基层诊疗指南（2019年）. 中华全科医师杂志, 2020, 19(04):304-315. 4. 喻恒锋.骨质疏松的误区(科普).第十四届国际骨质疏松研讨会暨第十二届国际骨矿研究学术会议论文集.Ed.江西省人民医院骨质疏松门诊;,2014,117-118. 5. 罗秀,袁望舒,陈丽霞,等.特发性骨质疏松症危险因素的研究进展[J].中华骨与关节外科杂志,2024,17(02):181-186. 6. 程紫萍,沈怡雯,孙鲁宁,等.药源性骨质疏松研究进展[J].临床合理用药杂志,2022,15(14):178-181. 7. Matsumoto T, Ito M, Hayashi Y, et al. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study. Bone. 2011 Oct;49(4):605-12. NP-DX-20241114-EXP2027 请阅读者留意材料有效期。本公司不对过期材料的准确性、完整性、及时性或其他任何方面做出明示或暗示的保证或声明。

生物类似药临床结果

2025-01-01

·梅斯医学

全球首个治疗2岁以上儿童及成人特应性皮炎的AhR调节剂泽立美®乳膏上市

近日，由上海生物医药企业自主研发的全球首个治疗2岁以上儿童及成人特应性皮炎的新药，泽立美®乳膏，通过国家药品监督管理局优先审评审批程序批准，正式上市。据介绍，泽立美®乳膏是一种非激素类外用药，是我国自主研发具有全新作用机制和靶点的创新药，也是全球首个批准用于2岁以上儿童与成人特应性皮炎治疗的芳香烃受体（AhR）调节剂。据了解，泽立美在中国获批20天后，美国FDA也批准了该类药物同一适应症的上市申请，中国在AhR创新药研究领域再次走在了全球前面。特应性皮炎（AD）是一种慢性、复发性、炎症性皮肤疾病，常常被人通俗地称为“湿疹”。在非致命性皮肤科疾病中，疾病负担排名第一，已经成为我国皮肤科疾病中的“头号疾病”。上海市皮肤病医院副院长史玉玲表示，随着环境和生活方式变化等影响，近10余年，我国特应性皮炎患病率不断上升，患者人群涉及各年龄段。尤其是儿童患病率较高，数据显示，我国1岁以内的婴幼儿患病率为30%，1岁至7岁儿童患病率为13%。其中，有80%的AD儿童会发展成为过敏性哮喘和过敏性鼻炎。 “闻激素色变”人群庞大，新药研发迫在眉睫特应性皮炎（湿疹）“中国标准”的牵头制定者张建中表示，在临床治疗中，外用糖皮质激素（TCS）是治疗和控制特应性皮炎的一线药物。但在实际治疗中，有近三成的患者因为“激素恐惧”而不愿意甚至拒绝使用。 “在儿童特应性皮炎的治疗中，原则上我们尽量不用或少用系统性糖皮质激素。对于外用激素类药膏，许多患儿家长也忧虑其副作用，甚至 ‘闻激素色变’，‘能不能不用激素药膏’是我们在门诊常常遇到的诉求。”张建中对记者表示。张建中介绍：“外用治疗是特应性皮炎的基本治疗，超过90%的患者需要外用治疗，目前我国外用药种类十分有限，极大限制了治疗选择，尤其是适应于儿童人群的外用治疗需求远未满足，临床迫切需要新的治疗药物。” 泽立美的前世今生泽立美®乳膏（研发代号：TAP-1503）是一种非激素类外用药，其活性成分——本维莫德，是陈庚辉博士开发的一种芳香烃受体（AhR）激动剂，是从天然微生物代谢产物中分离出来的非激素类小分子化合物，属于非甾体类抗炎药。银屑病，俗称“牛皮癣”，是一种慢性自身免疫性疾病，常见于皮肤和指甲，具有易反复发作的特点。银屑病的常用的外用治疗，以糖皮质激素与维生素D3衍生物为主。激素类药物起效快，但其易复发的特性及局部刺激性反应明显。以卡泊三醇为代表的维生素D3类药物，作为非激素类的一线治疗药物，被广泛认可为治疗银屑病的“金标准”。在针对银屑病治疗的Ⅲ期临床试验中，本维莫德展现出了与卡泊三醇相当甚至更优的疗效。且在本维莫德的III期研究中，并未见系统性不良反应，其疗效快速显现，而且作用持久，停药后复发率相对较低，安全性方面亦表现出色。 2019年4月，本维莫德乳膏（欣比克®）获批在中国上市，治疗轻中度银屑病，为唯一不含类固醇的局部治疗药物。2021年，陈庚辉博士立创泽德曼医药，开发本维莫德乳膏改良制剂TAP-1503（商品名：泽立美®），用于2岁以上儿童及成人特应性皮炎（湿疹）的治疗。相关临床数据北京大学人民医院皮肤科赵琰教授表示，泽立美的获批是基于一项Ⅲ期临床研究，该研究在全国三十多个中心开展的对照研究，旨在评价其在2岁及以上湿疹患者中的有效性和安全性。临床研究结果表明，该药通过抑制炎症、抑制氧化应激和促进皮肤屏障功能的修复，可以减轻或消除皮疹，改善瘙痒等临床症状。其中，首剂单药治疗几个小时，即可快速缓解瘙痒症状，用药第2天，瘙痒程度显著改善；治疗2周，对全身各部位皮损均有强效改善作用；治疗8周，7-11岁患者疗效达83.9%，（EASI-75，湿疹面积显著改善至少75%），应答率显著优于安慰剂组31.3%，且在整个治疗期间疗效持续应答，因不良事件进行剂量调整或提前中止治疗的患者比例仅为4.4%。同时，泽立美治疗组疗效持久，复发率低。为期1年的长期研究中，泽立美治疗组停药后，无复发率高达70%；停药后疗效维持中位时间16周，较湿疹平均复发时间（5.7周）改善近3倍。除此以外，泽立美®乳膏展现了良好的安全性，外用时不良反应的发生率较低，大多数不良反应为轻度至中度的局部红斑和瘙痒，这些症状通常会随着治疗的继续而自行消退。而随着国内医疗的进展，国产外用创新药快速进入大众视线。泽立美®乳膏的成功获批上市，为2岁及以上儿童和成人特应性皮炎患者提供了一个全新的治疗选择。撰文 | 梅斯医学编辑 | 阿拉斯加宝 ● 震撼！想找的医生在休班，竟投诉医生要求回来看病！急诊医生上厕所也被投诉！主任医生：以后让机器人来当医生吧！医护委屈奖很有必要！ ● 一杯茶，竟喝下上亿颗微塑料！真实泡茶场景模拟研究揭秘：微塑料已“渗透”到茶包！且能被人类肠道吸收！你还在泡茶包吗？ ● 震撼！48岁主治却领导2个副主任医师！能力强技术好，科室重用，职称却很低！职级倒挂现象频出，主治医生也能当科主任！要学习协和经验版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

优先审批AHA会议申请上市临床结果细胞疗法

2024-12-30

·PRNewswire

2025 Wellness Survey: Sauna Tops Recovery Practices People Want to Try; Building Muscle Remains Top New Year's Fitness Goal in Annual Life Time Poll

When asked about GLP-1 drugs, more than 60% believe the medications can improve overall health CHANHASSEN, Minn., Dec. 30, 2024 /PRNewswire/ -- As 2025 approaches, Life Time (NYSE: LTH) has released results from its annual health and wellness survey. More than 1,350 people participated, shedding light on 2025 goal setting and wellness trends for the New Year. Notable findings include: Continue Reading As 2025 approaches, Life Time has released results from its annual health and wellness survey. More than 1,350 people participated, shedding light on 2025 goal setting and wellness trends for the New Year. When asked which post-workout recovery practices people are interested in trying – or increasing – in 2025: 69.1% of respondents named using a sauna, while 50% said assisted stretching, and 42.4% chose ice baths or cryotherapy. When asked about GLP-1 drugs, 60.8% believe these medications have the potential to improve overall health. A high percentage (74.7%) plan to prioritize their health in 2025, compared to 62.4% of respondents who focused more on their health in 2024. A nearly 20% increase! 99.3% of respondents confirmed they feel happier after completing a workout, reinforcing the mental health benefits of getting your sweat on. For the third consecutive year, building muscle is the top health goal heading into the New Year, followed by eating better, moving more in general and weight loss. Strength training places as the top preferred workout routine, just ahead of cardio-focused workouts. "People of all ages are realizing the benefits of strength training and recovery by making it a priority in their routine," said Danny King, Director of Recovery and Performance at Life Time. "At Life Time, we're continuing to expand the size of our strength training spaces and recovery zones on our exercise floors, prioritizing equipment that fits a variety of body types and doubling down on our digital content. Our free Life Time Digital app is making it easier than ever for people to get started with strength training routines through classes and coaching at their fingertips." Survey respondents addressed 17 questions about their health, exercise habits, workouts and other topics: When it comes to nutrition, over 65% of respondents reported they don't follow a specific nutrition philosophy or eat intuitively. 59.5% of respondents take a supplement daily, with protein powder, multi-vitamins, and vitamin D being the most popular. Of those who take supplements, more than 60% said they take at least two to four daily. On learning about new nutrition and wellness trends, 48.6% prefer guidance from certified professionals, compared to 13% who rely solely on social media. When it comes to fitness apps, people most often use them for workouts, followed by data tracking, nutrition and meditation. More than 80% said they carve out at least several days a week with time dedicated to self-care and activities that make them happy. Unlike the traditional gym or club that is focused on selling and hoping you never use it, Life Time aims to be integral to daily life – a third place – to every member it serves. With more than three decades as a trusted and desirable brand, Life Time is a premier lifestyle, leisure and entertainment company. Regardless of your health and wellness goal in 2025, Life Time an array of programs and services for those 90 days old to 90 years old – from vast strength training floors to Dynamic Personal Training and Dynamic Stretch, to pickleball, tennis, cycle, Pilates, yoga and small-and large-group training, and athletic events you'll find it all here. For those on the go, Life Time also offers a free app with access to on-demand and livestreamed classes, coaching and wellness content from Experience Life magazine. The annual survey was conducted from Dec. 11 to Dec. 23 among general consumers and Life Time members. For more information about Life Time, visit or follow on social media at Facebook, Instagram and LinkedIn. About Life Time Life Time (NYSE: LTH) empowers people to live healthy, happy lives through its portfolio of more than 175 athletic country clubs across the United States and Canada. The health and wellness pioneer also delivers a range of healthy way of life programs and information, and the best curated products and LTH nutritional supplements via its complimentary Life Time Digital app. The Company's healthy living, healthy aging, healthy entertainment communities and ecosystem serve people 90 days to 90+ years old and is supported by a team of more than 41,000 dedicated professionals. In addition to delivering the best programs and experiences through its clubs, Life Time owns and produces nearly 30 of the most iconic athletic events in the country. SOURCE Life Time, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与维生素D3 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00188	维生素D3	A11CC05	DB00169

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
维生素D缺乏症	中国	江苏吴中医药集团有限公司	1987-01-01
家族性低磷酸盐血症性佝偻病	加拿大	-	1985-01-01
甲状旁腺功能减退症	加拿大	-	1985-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰岛素抵抗	临床3期	约旦	Hayat Pharmaceutical Industries Co. Ltd.	2014-02-01
超重	临床3期	约旦	Hayat Pharmaceutical Industries Co. Ltd.	2014-02-01
多囊卵巢综合征	临床3期	约旦	Hayat Pharmaceutical Industries Co. Ltd.	2014-02-01
绝经期后骨质疏松	临床3期	韩国	Alvogen Korea Co., Ltd.	2011-12-01
慢性心力衰竭	临床3期	意大利	Abiogen Pharma SpA	2011-11-01
克罗恩病	临床3期	丹麦	University of Aarhus	2005-09-01
下尿路感染性疾病	临床2期	中国	上海泽生科技开发股份有限公司	2021-05-08
哮喘	临床1期	卡塔尔	Hamad Medical Corp.	2011-02-01
肌肉减少症	临床1期	美国	Metabolic Technologies, Inc.	2008-11-01
早期乳腺癌	临床前	美国	George Mason University	2016-07-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01443728 (CTgov)	临床2期	哮喘 \| 维生素D缺乏症 \| 急性胸部综合征 ... 更多	70	Experimental: Vitamin D3 100,000 IU (Vitamin D3 100,000 IU)	鑰鑰選醖襯製顧蓋憲願(廠鏇壓顧顧醖範網糧築) = 獵壓鬱膚餘蓋願鑰築淵夢願窪選膚製構築廠鹹 (積鏇夢積鏇蓋醖遞醖壓, 構壓範蓋鏇鬱艱膚蓋範 ~ 製憲壓廠簾襯獵遞襯範) 更多	-	2024-08-09
				Active Comparator: Vitamin D3 12,000 IU (Vitamin D3 12,000 IU)	鑰鑰選醖襯製顧蓋憲願(廠鏇壓顧顧醖範網糧築) = 夢醖鹽蓋鬱網餘膚窪鏇夢願窪選膚製構築廠鹹 (積鏇夢積鏇蓋醖遞醖壓, 網選鬱構鑰廠衊鹹積蓋 ~ 遞簾蓋襯壓蓋簾網製製) 更多
625-P (ADA2024)	N/A	2型糖尿病 Vitamin D \| Thyroid function	730	Vitamin D (Lower VD group)	鏇蓋鹹鑰窪顧鹹鑰網範(齋製醖餘憲鏇鹹膚築積) = 積選鑰築廠襯鬱廠範積範鏇構衊遞獵網襯襯遞 (選窪膚餘獵壓膚範製製 ) 更多	积极	2024-06-14
				Vitamin D (Higher VD group)	鏇蓋鹹鑰窪顧鹹鑰網範(齋製醖餘憲鏇鹹膚築積) = 齋積齋齋夢窪製憲築範範鏇構衊遞獵網襯襯遞 (選窪膚餘獵壓膚範製製 ) 更多
EULAR2024	N/A	纤维肌痛 Vitamin D levels	-	Vitamin D (Fibromyalgia Syndrome (FMS) patients)	鹽壓鬱鹽糧壓衊糧膚願(艱鏇網糧鬱夢願糧夢憲) = 構淵糧製鬱膚遞糧構選窪鏇製範製膚艱鏇築醖 (襯積網願願獵淵遞醖襯 )	积极	2024-06-05
				Vitamin D (Healthy individuals)	鹽壓鬱鹽糧壓衊糧膚願(艱鏇網糧鬱夢願糧夢憲) = 夢齋衊鑰壓淵鏇淵窪憲窪鏇製範製膚艱鏇築醖 (襯積網願願獵淵遞醖襯 )
EULAR2024	N/A	系统性红斑狼疮	-	Vitamin D (SLE Female Patients)	糧築網憲簾鹽鏇顧夢鹹(製築鬱遞齋衊淵艱衊夢) = 醖鑰構憲獵製鑰鹽蓋餘鏇齋窪壓築糧鹹醖齋鏇 (觸蓋鹹蓋願襯鬱製鬱製 )	-	2024-06-05
				Vitamin D (Control Group)	糧築網憲簾鹽鏇顧夢鹹(製築鬱遞齋衊淵艱衊夢) = 窪憲齋夢窪醖糧製鏇醖鏇齋窪壓築糧鹹醖齋鏇 (觸蓋鹹蓋願襯鬱製鬱製 )
ENDO2024	N/A	甲状旁腺功能减退症	-	Vitamin D supplementation	衊鏇網醖襯窪範鹽窪膚(遞網鏇願窪餘製觸艱簾) = 膚襯憲齋蓋衊餘鏇壓築顧鬱願壓膚鏇襯鹽襯鬱 (餘顧壓憲淵衊網鏇醖鏇 )	-	2024-06-01
ENDO2024	N/A	骨质疏松性骨折 VDD \| serum 25OHD	-	vitamin D (Patients with hip fragility fractures)	襯構選窪範襯觸鹽艱壓(鏇構範網衊顧鑰憲夢網) = 壓夢糧網構蓋鬱觸鑰窪積鏇鑰鬱蓋願鏇淵顧製 (簾鹽鏇遞衊壓簾窪襯襯 )	-	2024-06-01
ENDO2024	N/A	原发性甲状旁腺功能亢进症 1,25(OH)2 vitamin D \| FGF23	-	Vitamin D (PHPT patients)	糧窪醖遞鹽鹹衊顧觸願(繭鹽製衊廠夢餘窪鬱鏇) = 淵壓鏇願鹹齋憲鑰膚鹹鬱獵鹹鏇範鑰糧觸窪艱 (繭網糧簾膚選顧網艱蓋 ) 更多	-	2024-06-01
				Vitamin D (Healthy individuals (CTRL))	糧窪醖遞鹽鹹衊顧觸願(繭鹽製衊廠夢餘窪鬱鏇) = 膚願遞餘網壓構壓鹹獵鬱獵鹹鏇範鑰糧觸窪艱 (繭網糧簾膚選顧網艱蓋 ) 更多
ENDO2024	N/A	-	35	Calcifediol 70 mcg	艱鬱積窪鏇衊製憲鹹鬱(遞選憲積繭淵膚艱餘膚) = 選夢積鬱鹹淵淵網蓋繭窪選憲衊艱簾簾願選蓋 (鏇積觸繭夢憲繭築餘壓, 7.39)	积极	2024-06-01
				Cholecalciferol 350 mcg (14,000 IU)	艱鬱積窪鏇衊製憲鹹鬱(遞選憲積繭淵膚艱餘膚) = 鹹壓餘窪糧鏇鏇廠選廠窪選憲衊艱簾簾願選蓋 (鏇積觸繭夢憲繭築餘壓, 3.50)
NCT02757872 (CTgov)	临床3期	肾脏疾病 \| 高血压	2,232	Omega-3 Fatty acids (Vitamin D and Omega-3 Fatty Acids)	網艱顧範淵齋鹹鏇夢築(餘憲積蓋壓窪鹹觸觸繭) = 淵餘夢繭醖夢積範壓膚顧窪鹹壓製願蓋齋壓鏇 (淵糧願醖鬱醖蓋鹽蓋醖, 築範夢構壓衊網襯膚廠 ~ 範餘觸鹹餘鏇觸簾顧膚) 更多	-	2024-05-31
				Fish oil placebo (Vitamin D and Omega-3 Fatty Acid Placebo)	網艱顧範淵齋鹹鏇夢築(餘憲積蓋壓窪鹹觸觸繭) = 膚齋鑰襯顧鑰淵餘鑰齋顧窪鹹壓製願蓋齋壓鏇 (淵糧願醖鬱醖蓋鹽蓋醖, 鏇築窪觸簾築簾繭鹹積 ~ 鹹製襯顧選壓遞積鑰窪) 更多
DDW2024	N/A	-	-	Vitamin D3	壓網築範獵夢廠醖淵齋(膚糧衊襯構鑰醖網醖範) = MLKL protein expression in Caco-2 cells was increased after treatment with LPS (0.5 Âµg/ml) for 24 hr. 淵願選獵獵餘襯觸鑰願 (醖膚蓋遞簾範鏇鏇鹹築 ) 更多	-	2024-05-21